The registrar will also accept payment by major credit cards (VISA/American Express/MasterCard only). For more information on the meeting, or for questions on registration, contact PDA (see FOR FURTHER INFORMATION CONTACT).

B. Accommodations

Attendees are responsible for their own accommodations. To make reservations, contact the Renaissance Washington Hotel (see ADDRESSES) and reference "the 2016 PDA/FDA Joint Regulatory Conference" to receive the PDA group rate. Room rates are: Single: \$305 plus 14.5 percent State and local taxes. Requests will be processed on a first-come, first-served basis.

Transcripts: As soon as a transcript is available, it can be obtained in either hardcopy or on CD–ROM, after submission of a Freedom of Information request. The Freedom of Information office address is available on the Agency's Web site at http://www.fda.gov.

Dated: March 16, 2016.

Leslie Kux,

 $Associate\ Commissioner\ for\ Policy.$ [FR Doc. 2016–06366 Filed 3–21–16; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Environmental Health Sciences, Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel; Evaluation of the U01 Engineered Nanomaterials (ENMs) Grant Applications.

Date: April 4, 2016.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Sheraton Chapel Hill Hotel, 1 Europa Drive, Chapel Hill, NC 27517.

Contact Person: Leroy Worth, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, Nat. Institute of Environmental Health Sciences, P.O. Box 12233, MD EC–30/Room 3171, Research Triangle Park, NC 27709, (919) 541–0670, worth@niehs.nih.gov.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel; Small Business Innovation Research (SBIR) Applications Teleconference Review.

Date: April 7, 2016.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: NIEHS, Keystone Building, 530 Davis Drive, Suite 3118, Research Triangle Park, NC 27709, (Telephone Conference

Contact Person: Leroy Worth, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, Nat. Institute of Environmental Health Sciences, P.O. Box 12233, MD EC-30/ Room 3171, Research Triangle Park, NC 27709, (919) 541-0670, worth@niehs.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114,

Dated: March 15, 2016.

National Institutes of Health, HHS)

Carolyn Baum,

Program Analyst, Office of Federal Advisory Committee Policy.

Applied Toxicological Research and Testing,

[FR Doc. 2016–06337 Filed 3–21–16; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Development and Commercialization of Cancer Immunotherapy

AGENCY: National Institutes of Health, HHS.

11113.

ACTION: Notice.

SUMMARY: This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following U.S. Patents and Patent Applications to Midissia Therapeutics ("MIDISSIA") located in San Francisco, California, USA.

Intellectual Property

United States Provisional Patent Application No. 60/476,467, filed June 5, 2003, entitled "Immunogenic Peptides and Peptide Derivatives For The Treatment of Prostate And Breast Cancer Treatment" [HHS Reference No. E-116-2003/0-US-01]; International Patent Application No. PCT/US2004/ 17574 filed June 2, 2004 entitled "Immunogenic Peptides and Peptide Derivatives or The Treatment of Prostate And Breast Cancer Treatment" [HHS Reference No. E-116-2003/0-PCT-02]; United States Patent No.7,541,035, issued June 2, 2009, entitled "Immunogenic Peptides and Peptide Derivatives For The Treatment of Prostate And Breast Cancer Treatment" [HHS Reference No. E-116-2003/0-US-031: United States Patent No. 8.043.623. issued 25 Oct 2011, entitled "Immunogenic Peptides and Peptide Derivatives For The Treatment of Prostate And Breast Cancer Treatment" [HHS Reference No. E-116-2003/0-US-04]; United States Provisional Patent Application No. 61/915,948, filed December 13, 2013, entitled "Multi-Epitope TARP Peptide Vaccine and Uses Thereof" [HHS Reference No. E-047-2014/0-US-01]; International Patent Application No. PCT/US2014/ 070144 filed December 12, 2014 entitled "Multi-Epitope TARP Peptide Vaccine and Uses Thereof" [HHS Reference No. E-047-2014/0-PCT-02]; and all continuation applications, divisional applications and foreign counterpart applications claiming priority to the US provisional application no. 61/915, 948 and U.S. Provisional Application No. 62/248,964 filed October 30, 2015 titled "Compositions and Methods for the Treatment of HER2-Expressing Solid Tumors" [HHS Reference No. E-187-2015/0-US-01] and continuation applications, divisional applications and foreign counterpart applications claiming priority to the US provisional application no. 62/248,964.

The patent rights in these inventions have been assigned to the government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use may be limited to the use of Licensed Patent Rights for the following:

(1) Development and commercialization of a therapeutic cancer vaccine specifically in combination with Licensee's proprietary or exclusively in-licensed vectors/adjuvants and ME-TARP;

(2) Development and commercialization of a combination product using Licensee's proprietary or